NCT05962216 Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders
| NCT ID | NCT05962216 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dr. Albert Kar-Kin Chung |
| Condition | Psychosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-07-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2023-07-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Not only being the mainstay of treatment for schizophrenia spectrum psychotic disorders, antipsychotics, especially the second-generation antipsychotics (SGAs) have also been recommended as augmenting agents for treating depression. Dopaminergic agents, including both dopamine D2/D3 antagonists and dopamine partial D2 agonists, have been effective for treating psychosis and schizophrenia. Amongst all SGAs, those with partial D2 agonistic property are generally acknowledged to have better side-effect profiles with lower incidence of extrapyramidal side-effects, prolactin increase, weight gain, QTc prolongation, and metabolic syndrome, as well as more efficacious in alleviating depressive symptoms. Up-to-date, three SGAs, namely aripiprazole, brexpiprazole and cariprazine, are known to possess such partial D2 agonism. ReSD-HK study is part of the ReSD Asian Study aiming to carefully evaluate a cohort of patients prescribed with brexpiprazole on its efficacy and tolerability as treatment for schizophrenia and/or depression in a real-life clinical setting.
Eligibility Criteria
Inclusion Criteria: * Age: 18- 65 years old at the time of enrollment * Able to read and communicate in English and/or Chinese * Able to give informed consent * Has been diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), or International Statistical Classification of Diseases and Related Health Problems 10th revision (ICD-10) to have either Psychotic Disorders (F10-F19.5, F20-23, F25, F32-F33) * is receiving brexpiprazole as treatment for less than 4 weeks at the time of recruitment Exclusion Criteria: * Age \<18 years old * Unable to read English or Chinese * Unable to give informed consent * Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation (ICD-10 F70-73)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05962216 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Psychosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05962216 currently recruiting?
Yes, NCT05962216 is actively recruiting participants. Contact the research team at Chungkka@hku.hk for enrollment information.
Where is the NCT05962216 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT05962216 clinical trial?
NCT05962216 is sponsored by Dr. Albert Kar-Kin Chung. The trial plans to enroll 40 participants.